Indivior (NASDAQ:INDV) Sets New 12-Month High – Here’s What Happened

Indivior PLC (NASDAQ:INDV)’s share price hit a new 52-week high during trading on Wednesday . The company traded as high as $32.45 and last traded at $32.5030, with a volume of 371 shares. The stock had previously closed at $32.26.

Analyst Upgrades and Downgrades

INDV has been the subject of several recent research reports. HC Wainwright boosted their price target on Indivior from $28.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, November 3rd. Northland Securities set a $40.00 price objective on Indivior in a research report on Friday, October 31st. Piper Sandler reiterated an “overweight” rating and set a $41.00 target price (up previously from $27.00) on shares of Indivior in a research report on Friday, October 31st. Finally, Jefferies Financial Group started coverage on Indivior in a research note on Tuesday, July 22nd. They set a “buy” rating and a $20.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Indivior currently has an average rating of “Buy” and an average price target of $32.17.

Indivior Price Performance

The company has a market cap of $4.38 billion, a P/E ratio of 51.25 and a beta of 0.68. The firm’s 50-day moving average is $25.86 and its two-hundred day moving average is $20.01.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.72 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.34. The business had revenue of $314.00 million during the quarter, compared to analysts’ expectations of $257.66 million. Indivior had a net margin of 6.65% and a negative return on equity of 86.28%. Indivior has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Indivior PLC will post 1.22 EPS for the current year.

Hedge Funds Weigh In On Indivior

Several large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Indivior by 16.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock worth $71,000 after buying an additional 666 shares during the period. CWM LLC bought a new position in Indivior in the 3rd quarter valued at $25,000. Quarry LP purchased a new stake in Indivior in the third quarter worth $26,000. Raymond James Financial Inc. purchased a new stake in Indivior in the second quarter worth $26,000. Finally, Campbell & CO Investment Adviser LLC boosted its stake in shares of Indivior by 3.5% during the third quarter. Campbell & CO Investment Adviser LLC now owns 53,782 shares of the company’s stock valued at $1,297,000 after purchasing an additional 1,834 shares during the period. Institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.